COVID-19: Elucidating monoclonal and polyclonal seroantibody responses to the COVID-19 viral envelope
COVID-19:阐明对 COVID-19 病毒包膜的单克隆和多克隆血清抗体反应
基本信息
- 批准号:10513290
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-10-01 至 2024-09-30
- 项目状态:已结题
- 来源:
- 关键词:2019-nCoVAcuteAffinity ChromatographyAmericanAnimalsAntibodiesAntibody ResponseAntigensAwardB-LymphocytesBindingBinding SitesBiochemicalBiological AssayCOVID-19COVID-19 pandemicCOVID-19 patientCOVID-19 preventionCategoriesCellsCessation of lifeCharacteristicsChargeCodon NucleotidesCoronavirusDiseaseDoctor of PhilosophyElectrophoresisEnrollmentEpitope MappingEpitopesFamilyFractionationGoalsHIVHandHealthHealthcare SystemsHumanImmunityImmunoglobulin AImmunoglobulin GIndividualInfectionInpatientsIsoelectric PointKnowledgeLibrariesMapsMarylandMass Spectrum AnalysisMedicalMembrane GlycoproteinsMemory B-LymphocyteMethodsMonoclonal AntibodiesNucleoproteinsOutpatientsPatientsPersonsPhasePlasmaPlasmablastPlasmidsPrevention strategyProductionProteinsProtocols documentationResearchRunningSARS-CoV-2 antibodySARS-CoV-2 infectionSARS-CoV-2 spike proteinSamplingSystemTechniquesTestingUnited StatesUniversitiesVaccinesVeteransViralVirusX-Ray Crystallographybiosafety level 3 facilityconvalescent plasmaenv Gene Productsexperienceexperimental studyinterestmultiple myeloma M Proteinneutralizing antibodynovel therapeuticsnovel vaccinespandemic diseaseparticipant enrollmentpolyclonal antibodyprogramsreceptor bindingresponsetreatment strategy
项目摘要
Background/Rationale: As the Coronavirus Disease 2019 (COVID-19) epidemic expands across the United
States and the world, there are no proven therapies and little information is known regarding on immunity to
this virus. At this stage of the pandemic, all prevention and treatment strategies that show promise must be
explored. This proposal will focus on the polyclonal and monoclonal antibody responses to the severe acute
respiratory syndrome coronavirus-2 (SARS-CoV-2) envelope.
Objectives: The overarching goal of this program is to obtain a comprehensive understanding of the
polyclonal and monoclonal response to the SARS-CoV-2 envelope E, M, and S proteins. The specific aims of
this proposal are: 1) Deconvolute the polyclonal antibody response against the viral envelope of SARS-CoV-2;
2) Isolate neutralizing and non-neutralizing monoclonal antibodies against various epitopes of spike protein (S),
envelope protein (E), and membrane glycoprotein (M) of SARS-CoV-2; and 3) Map the corresponding
epitope(s) of the monoclonal antibodies.
Methods: We will obtain paired, acute and convalescent, samples from 60 inpatients and outpatients with
COVID-19 (30 have already been enrolled from the VA Maryland Health Care System and the University of
Maryland Medical System). We will screen samples by binding, live and pseudovirus neutralization. In this
proposal, we also will have access to BSL3 facilities on this campus that run neutralization assay with live virus
by one of the world experts in coronaviruses (Matt Frieman, PhD). Donors will be ranked on the basis of both
neutralization potency and breadth, and binding. The top three donors in each of the inpatient and outpatient
groups will be chosen for further study (top anti-RBD neutralization and breath, top anti- receptor binding domain
(RBD)-depleted plasma neutralization and breath, and top spike binding titers with non-neutralizing plasma).
In these six individuals, the anti-envelope antibody will be affinity purified; and fractionated using free-
flow-electrophoresis. This technique can separate antibodies based on charge, which will lead to separation
based on targeted epitopes as well. Individual fractions will be tested by binding and neutralization; and
characteristic biochemical and functional signatures of antibodies targeting each epitope will be ascertained.
Fractions of interest (different for each donor depending if neutralization or binding is targeted) will be sent for
mass spectrometry. B cell libraries will also be made from the convalescent IgG and IgA memory B cell pools;
and they will be interrogated using three complementary techniques including - acute phase plasmablast
repertoire analysis, subtraction analysis, and antigen baiting to identify potential antibodies.
Finally, mass spectrometry will be used to rank antibody candidates. 40 monoclonal antibodies (mAbs)
will be made and again be screened by neutralization potency, breadth, and isoelectric point, with top neutralizing
and binding antibodies (matching the respective profiles of the fractions that were targeted) to be moved forward
for fine epitope analysis by X-ray crystallography.
Impact: If successful, this project will yield a substantial understanding of neutralizing/non-neutralizing
antibodies and epitopes in COVID-19 disease, providing mAbs that can be moved into animal/human testing.
This research has direct relevance to the health of Veterans as any monoclonal antibodies isolated can
potentially be used for treatment and/or prevention of COVID-19.
背景/依据:随着2019年冠状病毒病(COVID-19)疫情在美国各地的蔓延,
在美国和全世界,没有经过证实的治疗方法,关于免疫力的信息也很少。
这个病毒。在这一流行病的现阶段,所有有希望的预防和治疗战略都必须
探讨了本建议将集中在多克隆和单克隆抗体反应的严重急性
呼吸综合征冠状病毒2型(SARS-CoV-2)包膜。
目标:该计划的总体目标是获得全面了解
对SARS-CoV-2包膜E、M和S蛋白的多克隆和单克隆应答。的具体目标
本研究的主要内容是:1)解卷积SARS-CoV-2病毒包膜的多克隆抗体反应;
2)分离针对刺突蛋白(S)的各种表位的中和和非中和单克隆抗体,
SARS-CoV-2的囊膜蛋白(E)和膜糖蛋白(M); 3)绘制相应的
单克隆抗体的表位。
方法:我们将从60例住院和门诊的急性和恢复期患者中获得配对样本,
COVID-19(30人已经从弗吉尼亚州马里兰州卫生保健系统和弗吉尼亚大学入学)
马里兰州医疗系统)。我们将通过结合、活病毒和假病毒中和来筛选样品。在这
根据这项提议,我们还可以使用该园区的BSL 3设施,这些设施可以使用活病毒进行中和试验
由世界冠状病毒专家之一(Matt Frieman博士)。捐助者将根据这两个因素进行排名
中和的效力和广度,以及结合力。住院病人和门诊病人的前三名捐赠者
将选择组进行进一步研究(最高抗RBD中和和呼吸,最高抗受体结合结构域
(RBD)耗尽的血浆中和和呼吸,以及非中和血浆的最高峰结合滴度)。
在这六个个体中,抗包膜抗体将被亲和纯化;并且使用游离的抗包膜抗体进行分级。
流动电泳这种技术可以根据电荷分离抗体,这将导致分离
也是基于靶向表位。将通过结合和中和对单个组分进行检测;以及
将确定靶向每个表位的抗体的特征性生物化学和功能特征。
感兴趣的部分(取决于靶向中和或结合,每个供体不同)将被发送至
质谱分析法来B细胞文库也将由恢复期IgG和伊加记忆B细胞库制备;
并将使用三种互补技术对其进行询问,包括急性期浆母细胞
库分析、减法分析和抗原诱食以鉴定潜在的抗体。
最后,将使用质谱法对候选抗体进行排序。40种单克隆抗体(mAb)
将制成并再次通过中和效力、宽度和等电点进行筛选,以中和最高
和结合抗体(与靶向的级分的相应谱匹配)向前移动
用于通过X射线晶体学进行精细表位分析。
影响:如果成功,该项目将产生对中和/非中和的实质性理解
新冠病毒病中的抗体和表位,提供可用于动物/人类测试的mAb。
这项研究与退伍军人的健康直接相关,因为任何分离的单克隆抗体都可以
可能用于治疗和/或预防COVID-19。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mohammad Mohseni Sajadi其他文献
Mohammad Mohseni Sajadi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mohammad Mohseni Sajadi', 18)}}的其他基金
Engineering of pan-neutralizing anti-HIV envelope antibodies
全中和抗 HIV 包膜抗体的工程
- 批准号:
10304133 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Engineering of pan-neutralizing anti-HIV envelope antibodies
全中和抗 HIV 包膜抗体的工程
- 批准号:
9927080 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Engineering of pan-neutralizing anti-HIV envelope antibodies
全中和抗 HIV 包膜抗体的工程
- 批准号:
10524019 - 财政年份:2019
- 资助金额:
-- - 项目类别:
Engineering of pan-neutralizing anti-HIV envelope antibodies
全中和抗 HIV 包膜抗体的工程
- 批准号:
10064993 - 财政年份:2019
- 资助金额:
-- - 项目类别:
HIV-1 acidic epitope discovery from broadly neutralizing seroantibodies
从广泛中和血清抗体中发现 HIV-1 酸性表位
- 批准号:
9182870 - 财政年份:2014
- 资助金额:
-- - 项目类别:
Discovery of acidic epitopes for HIV-1 broadly neutralizing seroantibodies
发现 HIV-1 广泛中和血清抗体的酸性表位
- 批准号:
9788183 - 财政年份:2014
- 资助金额:
-- - 项目类别:
HIV-1 acidic epitope discovery from broadly neutralizing seroantibodies
从广泛中和血清抗体中发现 HIV-1 酸性表位
- 批准号:
8968228 - 财政年份:2014
- 资助金额:
-- - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Standard Grant